Ionis Pharmaceuticals and Novartis announced that pelacarsen, their Lp(a) reducer, failed to meet the primary cardiovascular event endpoint in the Phase 3 Lp(a)HORIZON trial, even though it effectively lowered Lp(a) levels.

The trial’s topline results come from Lp(a)HORIZON, a large study enrolling 8,323 patients with established cardiovascular disease who were randomized to pelacarsen or placebo.

Despite the setback on efficacy, the safety profile of pelacarsen was described as acceptable in the filing.

Near-term trading setup showed slight upside pressure with a support around 57.70 and resistance near 58.11, as momentum indicators offered a mixed signal for a potential move.

Valuation remains stretched, with Ionis’ forward earnings multiple around 91, reflecting a high-growth biotech premium amid near-term volatility.

Some analysts argue the stock’s recent pullback may be overdone and that patient investors could see value as the pipeline advances, though the high multiple persists.

Ionis ended June with about $2.1 billion in cash and short-term investments, highlighting commercial momentum from TRYNGOLZA and DAWNZERA, which together guide 2026 sales in the roughly $210–230 million range.

The pelacarsen setback could trigger changes to development plans, influence investor considerations, and affect future regulatory expectations.

Investors should watch the September 22, 2026 FDA action date for zilganersen, as sentiment remains risk-off until clarity emerges.

Ionis’ near-term performance hinges on successfully executing its remaining pipeline and launches to offset financial strain and preserve investor confidence.

Insider trading data show repeated heavy selling by executives over six months, with few notable purchases, potentially shaping investor perception.

Despite the pelacarsen setback, Ionis has growth opportunities through recently approved drugs TRYNGOLZA and DAWNZERA, which may drive recurring revenue as adoption and payer confidence grow.